Veradigm (MDRX) Stock Price
Veradigm Price
Over the last 20 years Veradigm grew revenue by 9.2% annually, reaching 588.02 M USD. Earnings per share have grown at 17.2% per year over the last 17 years. For Veradigm, the net margin of -14.7% is down versus -11.2% a few years ago. The consensus 12-month price target for Veradigm is 18.50 USD, about 293.6% above where the stock trades today. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 17% above its 52-week low.
Veradigm stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Veradigm over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Veradigm stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Veradigm's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Veradigm Price |
|---|---|
| 9/18/2026 | 4.70 USD |
| 9/17/2026 | 4.80 USD |
| 9/16/2026 | 4.88 USD |
| 9/15/2026 | 4.86 USD |
| 9/14/2026 | 4.85 USD |
| 9/13/2026 | 4.90 USD |
| 9/11/2026 | 4.60 USD |
| 9/10/2026 | 4.55 USD |
| 9/9/2026 | 4.65 USD |
| 9/8/2026 | 4.85 USD |
| 9/4/2026 | 4.81 USD |
| 9/3/2026 | 4.80 USD |
| 9/2/2026 | 4.70 USD |
| 9/1/2026 | 4.81 USD |
| 8/31/2026 | 4.80 USD |
| 8/28/2026 | 4.90 USD |
| 8/27/2026 | 4.85 USD |
| 8/26/2026 | 4.88 USD |
| 8/25/2026 | 4.80 USD |
| 8/24/2026 | 4.90 USD |
| 8/21/2026 | 4.97 USD |
| 8/20/2026 | 4.95 USD |
| 8/19/2026 | 4.96 USD |
| 8/18/2026 | 4.96 USD |
| 8/17/2026 | 4.99 USD |
| 8/14/2026 | 4.90 USD |
| 8/13/2026 | 5.00 USD |
| 8/12/2026 | 4.95 USD |
| 8/11/2026 | 4.90 USD |
| 8/10/2026 | 5.00 USD |
Veradigm Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Veradigm Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.38 | 1.39 | 1.55 | 1.50 | 1.75 | 1.63 | 1.50 | 0.58 | 0.59 | 0.59 | 0.59 | 0.58 | 0.60 | 0.63 | 0.67 | 0.70 |
| 0.29 | 0.65 | 11.76 | -3.36 | 16.83 | -6.69 | -7.97 | -61.58 | 1.91 | – | -0.51 | -0.34 | 3.43 | 4.31 | 5.72 | 5.71 |
| 39.58 | 40.19 | 41.64 | 42.22 | 41.40 | 35.17 | 37.62 | 44.71 | 52.38 | 52.38 | 52.38 | 52.38 | 52.38 | 52.38 | 52.38 | 52.38 |
| 545.00 | 557.00 | 645.00 | 632.00 | 724.00 | 574.00 | 565.00 | 258.00 | 308.00 | 308.00 | 306.43 | 305.38 | 315.86 | 329.48 | 348.33 | 368.24 |
| -39.00 | 31.00 | 67.00 | 12.00 | -95.00 | -99.00 | -57.00 | 75.00 | -62.00 | -27.00 | 63.00 | 66.00 | 88.00 | 104.00 | 125.00 | 148.00 |
| -2.83 | 2.24 | 4.33 | 0.80 | -5.43 | -6.07 | -3.79 | 13.00 | -10.54 | -4.59 | 10.77 | 11.32 | 14.59 | 16.53 | 18.80 | 21.05 |
| -66.00 | -2.00 | -25.00 | -196.00 | 363.00 | -182.00 | 700.00 | 134.00 | -86.00 | -86.00 | 25.00 | 32.00 | 46.00 | 57.00 | 71.00 | 87.00 |
| -36.54 | -96.97 | 1,150.00 | 684.00 | -285.20 | -150.14 | -484.62 | -80.86 | -164.18 | – | -129.07 | 28.00 | 43.75 | 23.91 | 24.56 | 22.54 |
| 180.30 | 191.50 | 183.20 | 180.73 | 175.40 | 164.40 | 150.85 | 120.10 | 112.00 | 128.90 | 128.90 | 128.90 | 128.90 | 128.90 | 128.90 | 128.90 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Veradigm generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Veradigm retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Veradigm's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Veradigm has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Veradigm's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Veradigm stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Veradigm Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Veradigm business model & stock analysis
Veradigm SWOT Analysis
Strengths
1. Strong Reputation: Allscripts Healthcare Solutions Inc has established itself as a reputable and trusted provider of healthcare solutions in the industry.
2. Comprehensive Product Portfolio: The company offers a wide range of healthcare software products and services, including electronic health records (EHRs) and practice management systems.
3. Established Customer Base: Allscripts has a large and diverse customer base, including healthcare organizations of varying sizes and specialties.
Weaknesses
1. Intense Competition: Allscripts faces significant competition from other healthcare software companies, which may impact its market share and pricing power.
2. Reliance on Third-Party Systems: The company's software solutions often integrate with third-party systems, which can introduce risks related to interoperability and compatibility.
3. Limited Global Presence: Allscripts' market presence outside of the United States is relatively small compared to some of its competitors.
Opportunities
1. Growing Healthcare IT Market: The increasing digitization of healthcare and the demand for efficient solutions present opportunities for Allscripts to expand its customer base.
2. Expansion into Telehealth: The COVID-19 pandemic has accelerated the adoption of telehealth. Allscripts can explore opportunities to enhance its telehealth capabilities and tap into this growing market.
3. Strategic Partnerships: Collaborating with healthcare providers, technology companies, and other stakeholders can enable Allscripts to develop innovative solutions and expand its market reach.
Threats
1. Regulatory Changes: Frequent changes in healthcare regulations can create challenges for Allscripts in terms of compliance and adapting its software to new requirements.
2. Data Security Risks: The increasing volume and sensitivity of healthcare data pose significant risks in terms of data breaches and cybersecurity threats.
3. Economic Uncertainty: Economic downturns or budget constraints within the healthcare industry can impact the purchasing decisions of potential customers, affecting Allscripts' revenue.
Veradigm Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Veradigm Segments
Veradigm Revenue by Segment (1/5)
3 Years
5 Years
Max
Details
Veradigm Revenue by Segment (2/5)
3 Years
5 Years
10 Years
25 Years
Max
Details
Veradigm Revenue by Segment (3/5)
3 Years
Max
Details
Veradigm Revenue by Segment (4/5)
3 Years
5 Years
Max
Details
Veradigm Revenue by Segment (5/5)
3 Years
5 Years
Max
Details
Veradigm Revenue by Region
3 Years
5 Years
Max
Details
Veradigm Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Veradigm historical P/E ratio, EBIT multiple, and P/S ratio
Veradigm annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Veradigm's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Veradigm's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Veradigm's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Veradigm shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Veradigm forecasts and price targets in September 2026
Analyst Price Targets 2026Veradigm Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 1/31/2025 | Maintained | Equal Weight | 64 | |
| 5/28/2024 | Maintained | Buy | 58 | |
| 3/19/2024 | Downgrade | BuyHold | 54 | |
| 1/19/2024 | Maintained | Outperform | 48 | |
| 11/14/2023 | Maintained | Equal Weight | 64 | |
| 10/10/2023 | Maintained | Equal Weight | 64 | |
| 7/6/2023 | Downgrade | BuyHold | – | |
| 2/1/2023 | Downgrade | OverweightNeutral | 54 | |
| 12/7/2022 | Upgrade | HoldBuy | – | |
| 11/18/2022 | Maintained | Underweight | 53 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Veradigm Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/6/2026 | 0.08USD | - | 144.10 MUSD | - | 2026 Q3 |
| 8/31/2026 | 0.09USD | - | 144.40 MUSD | - | 2026 Q2 |
| 5/26/2026 | 0.17USD | 0.22USD | 152.00 MUSD | - | 2026 Q1 |
| 3/16/2026 | 0.07USD | - | 150.55 MUSD | - | 2025 Q4 |
| 11/7/2025 | 0.05USD | 0.05USD | 144.60 MUSD | - | 2025 Q3 |
| 8/8/2025 | 0.07USD | 0.07USD | 145.60 MUSD | - | 2025 Q2 |
| 3/18/2025 | 0.07USD | 0.06USD | 147.75 MUSD | - | 2025 Q1 |
| 2/28/2025 | 0.31USD | 0.19USD | 169.96 MUSD | - | 2024 Q4 |
| 11/1/2024 | 0.21USD | 0.27USD | 161.30 MUSD | - | 2024 Q3 |
| 8/2/2024 | 0.17USD | 0.22USD | 152.00 MUSD | - | 2024 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Veradigm stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Veradigm shareholder structure
| % | Name |
|---|---|
3.58127% | |
0.67222% | |
0.25571% | |
0.25313% | |
0.20371% | |
0.10086% |
Veradigm Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
19.60% | SEC ↗ | |
19.60% | SEC ↗ | |
19.60% | SEC ↗ | |
19.60% | SEC ↗ | |
19.60% | SEC ↗ | |
19.60% | SEC ↗ | |
19.60% | SEC ↗ | |
19.60% | SEC ↗ | |
19.50% | SEC ↗ | |
18.30% | SEC ↗ |
Veradigm Executives and Management Board
12 members · avg. age 58 · 42 % women
Ms. Tejal Vakharia (49)
Senior Vice President, General Counsel - Marketing and Government Affairs
2.08 M USD
Management
Mr. Donald Trigg (54)
Chief Executive Officer, Director · since 2025
Mr. Leland Westerfield (54)
Interim Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Ms. Lisa Hammond (50)
Chief Human Resources Officer, Senior Vice President
Ms. Jenny Gelinas
Vice President, Investor Relations · since 2021
Board of Directors
Mr. Dave Stevens (60)
Independent Director
Ms. Carol Zierhoffer (62)
Lead Independent Director
Mr. Louis Silverman (66)
Independent Chairman of the Board
Ms. Susan Rodriguez (61)
Director
Mr. Vinit Asar (59)
Independent Director
Mr. Bruce Felt (66)
Independent Director
Veradigm Supply Chain
Veradigm Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.64 | 0.73 | 0.83 | ||
| 2 | 0.34 | 0.38 | 0.71 | ||
| 3 | 0.11 | 0.30 | 0.68 | ||
| 4 | -0.47 | -0.02 | 0.67 | ||
| 5 | -0.24 | -0.07 | 0.61 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.37 | 0.66 | — | ||
| 2 | Oneview Health CDIs | -0.50 | -0.67 | — | |
| 3 | -0.11 | 0.06 | — | ||
| 4 | SOC Telemed A | -0.15 | -0.29 | — | |
| 5 | -0.53 | -0.73 | -0.79 |
Frequently asked questions about Veradigm
Allscripts Healthcare Solutions Inc is a leading healthcare technology company that provides innovative solutions and services to healthcare organizations. The business model of Allscripts revolves around the development and provision of electronic health record (EHR) systems, practice management software, and other healthcare IT solutions. By offering integrated platforms, Allscripts enables healthcare providers to streamline operations, improve patient care, and enhance clinical outcomes. With a focus on promoting interoperability and connectivity, Allscripts facilitates efficient data exchange across healthcare settings. By leveraging technology and data analytics, Allscripts aims to optimize workflows, enhance decision-making processes, and ultimately improve the overall delivery of healthcare services.
Allscripts Healthcare Solutions Inc is primarily active in the healthcare industry.
The main competitors of Allscripts Healthcare Solutions Inc in the market include Cerner Corporation, Epic Systems Corporation, and Meditech.
Allscripts Healthcare Solutions Inc is a leading healthcare information technology company established in 1986. The company features a rich history and background, having grown from a small startup to a global provider of electronic health records (EHR), practice management systems, and population health management solutions. Allscripts is dedicated to enhancing patient care by empowering healthcare organizations with innovative technology. With a strong presence in the healthcare industry, Allscripts serves over 180,000 physicians and more than 2,500 hospitals worldwide. Continuously evolving and expanding its offerings, Allscripts Healthcare Solutions Inc remains at the forefront of the digital healthcare revolution.
Allscripts Healthcare Solutions Inc has achieved several significant milestones in its history. The company has successfully launched innovative products, expanded its market share, and entered into strategic partnerships within the healthcare industry. Allscripts Healthcare Solutions Inc has also received industry recognition for its excellent performance and dedication to providing high-quality healthcare solutions. By continuously investing in research and development, the company has consistently improved its technology offerings, contributing to the overall advancement of healthcare services. With its commitment to excellence, Allscripts Healthcare Solutions Inc continues to shape the future of healthcare with its groundbreaking solutions and services.
Allscripts Healthcare Solutions Inc is primarily present in the United States of America.
Allscripts Healthcare Solutions Inc represents the values of innovation, collaboration, and patient-centered care. With a commitment to improving healthcare technology, Allscripts aims to transform the way healthcare is delivered and experienced. The company values a collaborative approach, working closely with healthcare providers and patients to develop solutions that enhance clinical outcomes and patient satisfaction. Allscripts prioritizes the use of advanced technology and data analytics to drive better healthcare decision-making and deliver personalized care. Through its comprehensive suite of software and services, Allscripts aims to empower healthcare organizations to deliver efficient, high-quality care to their patients.
Analysts currently set an average price target of 16.17 USD for the Veradigm stock (median: 18.50 USD), implying +244.0 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the Veradigm stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Veradigm to generate revenue of 583.20 M USD and earnings per share of 0.25 USD.
Converted at the current exchange rate, the Veradigm share trades at 4.10 EUR (4.70 USD).
The Veradigm share (MDRX) is listed on 4 stock exchanges, including: NASDAQ (MDRX), Frankfurt (AL21.F), München (AL21.MU), Düsseldorf (AL21.DU).
Allscripts Healthcare Solutions Inc is an American company specializing in providing IT solutions for healthcare providers. The company was founded in 1986 as a small software firm in Chicago and has since become one of the leading providers of electronic health records and other health IT solutions. Allscripts offers a wide range of products and services to meet the needs of healthcare providers of all sizes and types. The various business areas of Allscripts include hospitals and health systems, physician practices, accountable care organizations (ACOs), and pharmacies. Allscripts' products and services are designed to increase the efficiency of healthcare providers, improve the quality of patient care, and meet the growing demand for connected healthcare. In the hospital and health systems area, Allscripts offers a comprehensive portfolio of solutions to meet the complex requirements of large and complex health systems. This includes electronic health records, laboratory and imaging management, portfolio management, revenue cycle management, and reporting. In the physician practices area, Allscripts provides a variety of solutions to increase the efficiency of individual practices and smaller group practices. Products in this area include electronic health records, appointment scheduling, billing, prescription management, and patient portals. For ACOs, Allscripts offers a variety of solutions to support the community of healthcare facilities and providers. This includes solutions for collaboration management, population health management, and the automation of clinical workflows. Allscripts' solutions are also of interest to pharmacies. Allscripts offers solutions for optimizing inventory management, billing, and patient care. The company relies on state-of-the-art IT solutions and implements industry-leading methods for data analysis. Allscripts employs over 8,600 employees and has customers in over 190 countries. The company demonstrates its commitment to innovation in the healthcare industry through the development of new products and services. For example, a program to enhance the functionality of implanted pacemakers was recently introduced, which can be operated directly from a smartphone via a secure cloud system. With the introduction of new products and solutions, Allscripts aims to further expand its business in the healthcare sector and strengthen its position as a leading provider of health IT solutions. In summary, Allscripts Healthcare Solutions Inc is a leading provider of health IT solutions that offers a wide range of products and services for healthcare providers of all sizes and types. Allscripts aims to make healthcare more sustainable, digital, and connected, and to increase the efficiency of the healthcare system through innovative solutions.
The expected revenue of Veradigm is 583.20 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Veradigm is 32.67 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Veradigm is currently 18.54. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Veradigm stock.
The price-to-sales ratio (P/S) of Veradigm is currently 1.04. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Veradigm stock.
The Eulerpool Quality Score for Veradigm is 0/10.
The ISIN of Veradigm is US01988P1084. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Veradigm is 607917. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Veradigm is MDRX. The ticker symbol is used to trade Veradigm shares on the stock exchange.
Veradigm paid dividends every year for the past 0 years.
Veradigm is assigned to the 'Health' sector.
The dividends of Veradigm are distributed in USD.
Veradigm stock
Veradigm Peer Group
Veradigm Ticker
Veradigm FIGI
All fundamentals and in-depth analysis of Veradigm
Our stock analysis for Veradigm stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Veradigm. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.